Neuroscience and medicalisation: Sociological reflections on memory, medicine and the brain

Advances in Medical Sociology

Volumn 13, Issue , 2011, Pages 231-254

  Williams, Simon J ^a   Katz, Stephen ^a   Martin, Paul ^a  

^a NONE

Author keywords

Brain; Cognitive health; Enhancement; Medicalisation; Medicine; Memory; Neuroscience

Indexed keywords

EID: 84886433485     PISSN: 10576290     EISSN: None     Source Type: Book Series    
DOI: 10.1108/S1057-6290(2011)0000013014     Document Type: Article

References (77)

1. Abi-Rached, J. M., & Rose, N. (2010). The birth of the neuromolecular gaze. History of the Human Sciences (Special Issue on 'Neuroscience, power and culture'), 23(1), 11-36.
2. Abraham, J. (2009a). The pharmaceutical industry, the state and the NHS. In: J. Gabe & M. Calnan (Eds.), The new sociology of the health service (pp. 99-120). London: Routledge.
3. Abraham, J. (2009b). Sociology of pharmaceuticals development and regulation: A realist empirical research programme. In: S. J. Williams, J. Gabe & P. Davis (Eds.), Pharmaceuticals and society (pp. 54-70). Oxford: Blackwell.
4. Academy of Medical Sciences. (2008). Brain science, addictions and drugs. London: AMS.
5. Ballenger, J. F. (2006a). Self, senility, and Alzheimer's disease in modern America. Baltimore: Johns Hopkins University Press.
6. Ballenger, J. F. (2006b). The biomedical deconstruction of senility and the persistent stigmatization of old age in the United States. In: A. Leibing & L. Cohen (Eds.), Thinking about dementia: Culture, loss, and the anthropology of senility (pp. 106-120). New Brunswick, NJ: Rutgers University Press.
7. Barber, C. (2008). The medicated Americans: Antidepressant prescriptions on the rise. Scientific American, February, 37-48.
8. Barr, M., & Rose, D. (2009). The great ambivalence; factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication. In: S. J. Williams, J. Gabe & P. Davis (Eds.), Pharmaceuticals and society (pp. 126-139). Oxford: Blackwell.
9. Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005). Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology, 64(5), 834-841. (Pubitemid 40316322)
10. Blech, J. (2006). Inventing diseases and pushing pills. London: Routledge.
11. British Medical Association. (2007). Boosting your brain power: Ethical aspects of cognitive enhancements. London: BMA.
12. Brown, N. (2003). Hope against hype: Accountability in biopasts, presents and futures. Science Studies, 16(2), 3-21.
13. Brown, N., & Michael, M. (2003). A sociology of expectations: Retrospecting prospects and prospecting retrospects. Technology Assessment and Strategic Management, 15(1), 3-18. (Pubitemid 36533586)
14. Bruscoli, M., & Lovestone, S. (2004). Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics, 16(2), 129-140. (Pubitemid 38963102)
15. Clarke, A., Fishman, J., Fosket, J. R., Mamo, L., & Shim, J. (2003). Biomedicalization: Technoscientific transformations of health, illness and US biomedicine. American Sociological Review, 68(2), 161-194. (Pubitemid 36696071)
16. Conrad, P. (2005). The shifting engines of medicalization. Journal of Health and Social Behavior, 46(1), 3-14. (Pubitemid 41503889)
17. Conrad, P. (2007). The medicalisation of society. Baltimore: Johns Hopkins University Press.
18. Conrad, P., Mackie, T., & Mehrota, A. (2010). The costs of medicalization. Social Science and Medicine, 70(12), 1943-1947.
19. Crawford, M. R. (2008). The limits of neuro-talk. The New Atlantis: A Journal of Technology and Society, 19(Winter), 65-78. www.TheNewAlantis.com (Accessed 01/02/2011
20. Cutler, N. R., Sramek, J. J., Murphy, M. F., Riordan, H., Bieck, P., & Carta, A. (2010). The imoending crisis in CNS drug development in critical pathways to success in CNS drug development. Oxford, UK: Wiley-Blackwell. 10.1002/9781444318579.ch1
21. DeGrazia, D. (2005). Enhancement technologies and human identity. Journal of Medicine and Philosophy, 30(3), 261-283. (Pubitemid 40896520)
22. Department of Trade and Industry (DTI) Office of Science and Technology. (2005). Drugs Futures 2025. London: DTI.
23. Fox, N. J., & Ward, K. J. (2008). Pharma in the bedroomyand the kitcheny. The pharmaceuticalisation of daily life. Sociology of Health and Illness, 30(6), 856-868.
24. Franks, D. (2010). Neurosociology. New York: Springer.
25. Franks, D., & Smith, T. S. (Eds.). (1999). Mind, brain and society: Toward a neurosociology of emotion. Stamford, CT: JAI Press.
26. Frisoni, G., Canu, E., Geroldi, C., Zanetti, O., & Zacchi, V. (2006). Drug prescription in mild cognitive impairment: The physicians' perspective in Italy. International Journal of Geriatric Psychiatry, 21(11), 1071-1077. (Pubitemid 44762725)
27. Fullagar, S. (2009). Negotiating the neurochemical self: Anti-depressant consumption in women's recovery from depression. American Journal of Public Health, 13(3), 389-409.
28. Gibbon, S., & Novas, C. (Eds.). (2008). Biosocialities, genetics and the social sciences. London: Routledge.
29. Graham, J. E., & Ritchie, K. (2006). Mild cognitive impairment: Ethical considerations for nosological flexibility in human kinds. Philosophy, Psychiatry & Psychology, 13(1), 31-43.
30. Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(10 December), 702-705.
31. Greenberg, G. (2010). Manufacturing depression: The secret history of a modern disease. London: Bloomsbury.
32. Harris, J. (2007). Enhancing evolution: The ethical case for making better people. Princeton, NJ: Princeton University Press.
33. Healy, D. (2006). Let Them Eat Prozac: The unhealthy relationship between the pharmaceutical industry and depression. New York: New York University Press.
34. History of the Human Sciences. (2010). Special issue on neuroscience. Power and Culture, 23(1), 1-126.
35. Hogle, L. F. (2005). Enhancement technologies and the body. Annual Review of Anthropology, 34, 695-716. (Pubitemid 41638325)
36. Hogle, L. F. (2007). Emerging medical technologies. In: E. J. Hackett, O. Amsterdamska, M. Lynch & J. Wajcman (Eds.), The handbook of science and technology studies, 3e (pp. 841-873). Cambridge, MA: MIT Press.
37. http://Drugtopics.modernmedicine.com/Top+200+Drugs
38. Katz, S., & Marshall, B. L. (2002). Forever functional: Male sexual fitness and the aging body. Body & Society, 8(4), 43-70.
39. Katz, S., & Peters, K. R. (2008). Enhancing the mind? Memory medicine, dementia, and the aging brain. Journal of Aging Studies, 22(4), 348-355.
40. Kaufman, S., Shim, J. K., & Russ, A. J. (2004). Revisiting the biomedicalization of aging: Clinical trends and ethical challenges. The Gerontologist, 44(6), 731-738. (Pubitemid 39658450)
41. Kramer, P. D. (1994). Listening to Prozac. London: Fourth Estate.
42. Kroll-Smith, S. (2003). Popular media and 'excessive daytime sleepiness': A study of rhetorical authority in medical sociology. Sociology of Health & Illness, 25(6), 625-643. (Pubitemid 37229691)
43. Leibing, A. (2009). From the periphery to the center: Treating behavioural and psychological symptoms in dementia. In: J. Ballenger, P. Whitehouse, C. Lyketsos, P. Rabins & J. Karlawish (Eds.), Do we have a pill for that? Interdisciplinary perspectives on the development, use and evaluation of drugs in the treatment of dementia (pp. 74-97). Baltimore: The Johns Hopkins University Press.
44. Maasen, S., & Sutter, B. (2007). On willing selves: Neoliberal politics and the challenge of neuroscience. Bastingtoke: Macmillan.
45. Marshall, B. L., & Katz, S. (2006). From androgyny to androgens: Re-sexing the aging body. In: T. Calasanti & K. Slevin (Eds.), Age matters (pp. 75-97). London: Routledge.
46. Martin, E. (2007). Bipolar expeditions. Princeton, NJ: Princeton University Press.
47. Martin, P., & Ashcroft, R. (2005). Neuroscience, ethics and society: A review of the field. Background paper prepared for the 2005 Wellcome Trust Summer School on 'Neuroethics'.Retrieved fromwww.wellcome.ac.uk/stellent/groups/ .../@msh.../wtx027876.pdf
48. Martin, P., Brown, N., & Kraft, A. (2008). From bedside to bench? Communities of promise, translational research and the making of blood stem cells. Science as Culture, 17(1), 29-41.
49. Mental Health Foundation. (2010). New data shows overreliance on antidepressants, says Mental Health Foundation. Retrieved from ohttp://www.mentalhealth.org.uk/media/news-releases/news-releases-2009/ 21-april2009/?locale1/4enW Accessed on 30 November.
50. Miller, P., & Wilsdon, J. (Eds.). (2006). Better humans? The politics of human enhancement and life extension. London: Demos.
51. Moreira, T., May, C., & Bond, J. (2009). Mild cognitive impairment and the collective production of uncertainty. Social Studies of Science, 39(5), 665-690.
52. Moynihan, R. (2002). Disease-mongering: How doctors, drug companies, and insurers are making you feel sick. British Medical Journal, 324, 923.
53. Moynihan, R., & Cassels, A. (2005). Selling sickness. New York: Nation Books.
54. Moynihan, R., Health, I., & Henry, D. (2002). Selling sickness: The pharmaceutical industry and disease mongering. British Medical Journal, 324(13 April), 886-891.
55. Moynihan, R., & Henry, D. (2006). The fight against disease mongering: Generating knowledge for action. Public Library of Science - Medicine, Apr3(4), e191.
56. Moynihan, R., & Mintzes, B. (2010). Sex, lies & pharmaceuticals: How drug companies plan to profit from female sexual dysfunction. Vancouver, BC: Greystone Books.
57. Olfsun, M., & Marcus, S. (2009). National patterns in antidepressant medication treatment. Archives of General Psychiatry, 66(8), 848-856.
58. Petersen, R. C., Stevens, J. C., Ganguli,M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001). Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology, 56(9), 1132-1142.
59. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology, 56(March), 303-308. (Pubitemid 29120227)
60. Philosophy, Psychiatry, & Psychology. (2006). Special issue: Mild cognitive impairment, Vol. 13, No. 1.
61. Pickersgill, M. (2009). Between soma and society: Neuroscience and the ontology of psychopathology. BioSocieties, 4(1), 45-60.
62. Pickersgill, M., Cunningham-Burley, S., & Martin, P. A. (2011). Constituting neurologic subjects: Neuroscience, subjectivity, and the mundane significance of the brain. Subjectivity, 4(3), 346-365
63. Post, S. G. (2000). The concept of Alzheimer disease in a hypercognitive society. In: P. J. Whitehouse, K. Maurer & J. F. Ballenger (Eds.), Concepts of Alzheimer disease: Biological, clinical, and cultural perspectives (pp. 235-256). Baltimore: Johns Hopkins University Press.
64. Rose, N. (2007a). Beyond medicalisation? Lancet, 369, 700-701.
65. Rose, N. (2007b). The politics of life itself: Biomedicine, power and subjectivity in the twenty-first century. Princeton, NJ: Princeton University Press.
66. Schermer, M., Bolt, I., de Jongh, R., & Olivier, B. (2009). The future of pharmacological enhancements: Expectations and policies. Neuroethics, 2, 75-87.
67. Scott, S. (2006). The medicalisation of shyness: From social misfits to social fitness. Sociology of Health & Illness, 28(2), 133-155.
68. Shostak, S., Conrad, P., & Horwitz, A. V. (2008). Sequencing and its consequences: Path dependence and the relationship between genetics and medicalization. American Journal of Sociology, 114(Suppl.), S287-316.
69. Szymczak, J. E., & Conrad, P. (2006). Medicalizing the aging male body: Andropause and baldness. In: D. Rosenfeld & C. A. Faircloth (Eds.), Medicalized masculinities (pp. 89-111). Philadelphia, PA: Temple University Press.
70. Tallis, R. (2009). Neurotrash. New Humanist, 124, 6(Nov/Dec). Retrieved from http://newhumanist.org.uk/2172/neurotrash. Accessed 30 January 2010
71. Turner, D. C., & Sahakian, B. J. (2006). Neuroethics of cognitive enhancement. BioSocieties, 1(1), 113-123.
72. Tuokko, H., Frerichs, R. J., & Kristjansson, B. (2001). Cognitive impairment, no dementia: Concepts and issues. International Psychogeriatrics, 13(Suppl. 1), 183-202. (Pubitemid 34171233)
73. Vidal, F. (2009). Brainhood, anthropological figure of modernity. History of the Human Sciences, 22(1), 5-36.
74. Whitehouse, P. J., & Moody, H. R. (2006). Mild cognitive impairment: A 'hardening of the categories'? Dementia: The International Journal of Social Research and Practice, 5(1), 11-25.
75. Whitehouse, P. J., & Juengst, E. T. (2005). Antiaging medicine and mild cognitive impairment: Practice and policy issues for geriatrics. Journal of the American Geriatrics Society, 53(8), 1417-1422. (Pubitemid 41602491)
76. Williams, S. J., Martin, P. & Gabe, J. (2011a). The pharmaceuticalisation of society: a framework for analysis. Sociology of Health & Illness, 33(5), 710-725.
77. Williams, S. J, Martin, P. & Gabe, J. (2011b). Evolving sociological analyses of "pharmaceuticalisation": A response to Abraham. Sociology of Health & Illness, 33(5), 729-730.